Wird geladen...

Community Clinical Practice Patterns and Mortality in Patients with Oncotype DX Intermediate Score: Who benefits from Chemotherapy?

BACKGROUND: Oncotype DX recurrence score (RS) is used as a tool for making decision about chemotherapy in hormone receptor-positive, HER2-negative breast cancer. There is no benefit of chemotherapy in node negative, RS 11–25, age ≥50 patients but the benefit of chemotherapy in the node positive grou...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer
Hauptverfasser: Ibraheem, Abiola F., Press, David J., Olopade, Olufunmilayo I., Huo, Dezheng
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2018
Schlagworte:
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6329644/
https://ncbi.nlm.nih.gov/pubmed/30387876
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.31818
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!